Nrf2 also contributes to the clearance of ROS in MDSCs and enables MDSCs to survive in the noxious TME.271 Systemic Nrf2-deletion or myeloid lineage Nrf2-deficiency in tumor-bearing mice could cause aberrant ROS accumulation in MDSCs, leading to increased susceptibility to cancer metastasis.272,273 The synthetic triterpenoid CDDO-Me (bardoxolone methyl, RTA402) is used for the treatment of chronic kidney disease, cancer, and other diseases.274 Recent studies have found that CDDO-Me could inhibit the immunosuppressive capacity of MDSCs by activating Nrf2 and inhibiting ROS generation in MDSCs. This evidence concerns the gene NFE2L2 and cancer.